These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 23078058)

  • 1. The status of fostamatinib in the treatment of rheumatoid arthritis.
    Morales-Torres J
    Expert Rev Clin Immunol; 2012 Sep; 8(7):609-15. PubMed ID: 23078058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial.
    Weinblatt ME; Kavanaugh A; Burgos-Vargas R; Dikranian AH; Medrano-Ramirez G; Morales-Torres JL; Murphy FT; Musser TK; Straniero N; Vicente-Gonzales AV; Grossbard E
    Arthritis Rheum; 2008 Nov; 58(11):3309-18. PubMed ID: 18975322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.
    Weinblatt ME; Kavanaugh A; Genovese MC; Musser TK; Grossbard EB; Magilavy DB
    N Engl J Med; 2010 Sep; 363(14):1303-12. PubMed ID: 20879879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents.
    Genovese MC; Kavanaugh A; Weinblatt ME; Peterfy C; DiCarlo J; White ML; O'Brien M; Grossbard EB; Magilavy DB
    Arthritis Rheum; 2011 Feb; 63(2):337-45. PubMed ID: 21279990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of spleen tyrosine kinase inhibitors in the management of rheumatoid arthritis.
    Scott DL
    Drugs; 2011 Jun; 71(9):1121-32. PubMed ID: 21711059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Weinblatt ME; Genovese MC; Ho M; Hollis S; Rosiak-Jedrychowicz K; Kavanaugh A; Millson DS; Leon G; Wang M; van der Heijde D
    Arthritis Rheumatol; 2014 Dec; 66(12):3255-64. PubMed ID: 25223724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic-pharmacodynamic modeling of fostamatinib efficacy on ACR20 to support dose selection in patients with rheumatoid arthritis (RA).
    Maringwa J; Kågedal M; Hamrén UW; Martin P; Cox E; Hamrén B
    J Clin Pharmacol; 2015 Mar; 55(3):328-35. PubMed ID: 25280085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial.
    Weinblatt ME; Kavanaugh A; Genovese MC; Jones DA; Musser TK; Grossbard EB; Magilavy DB
    J Rheumatol; 2013 Apr; 40(4):369-78. PubMed ID: 23378467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases.
    Bajpai M
    IDrugs; 2009 Mar; 12(3):174-85. PubMed ID: 19333898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Syk kinase inhibitors for rheumatoid arthritis: trials and tribulations.
    Boers M
    Arthritis Rheum; 2011 Feb; 63(2):329-30. PubMed ID: 21279987
    [No Abstract]   [Full Text] [Related]  

  • 11. Fostamatinib, a Syk-kinase inhibitor, does not affect methotrexate pharmacokinetics in patients with rheumatoid arthritis.
    Baluom M; Samara E; Grossbard EB; Lau DT
    J Clin Pharmacol; 2011 Sep; 51(9):1310-8. PubMed ID: 21209239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.
    Okamoto H; Kobayashi A
    N Engl J Med; 2011 Jan; 364(1):83-4; author reply 84. PubMed ID: 21208113
    [No Abstract]   [Full Text] [Related]  

  • 13. Spleen tyrosine kinase inhibitors for rheumatoid arthritis: where are we now?
    Scott IC; Scott DL
    Drugs; 2014 Mar; 74(4):415-22. PubMed ID: 24610702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of spleen tyrosine kinase in the treatment of rheumatoid arthritis.
    Nijjar JS; Tindell A; McInnes IB; Siebert S
    Rheumatology (Oxford); 2013 Sep; 52(9):1556-62. PubMed ID: 23861534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.
    Otón T; Silva-Fernández L; Andreu JL
    N Engl J Med; 2011 Jan; 364(1):83; author reply 84. PubMed ID: 21208114
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacokinetics of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in healthy human subjects following single and multiple oral dosing in three phase I studies.
    Baluom M; Grossbard EB; Mant T; Lau DT
    Br J Clin Pharmacol; 2013 Jul; 76(1):78-88. PubMed ID: 23190017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promising new treatments for rheumatoid arthritis - the kinase inhibitors.
    Yazici Y; Regens AL
    Bull NYU Hosp Jt Dis; 2011; 69(3):233-7. PubMed ID: 22035435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exposure vs. response of blood pressure in patients with rheumatoid arthritis following treatment with fostamatinib.
    Boström E; Öhrn F; Hanze E; Sandström M; Martin P; Wählby-Hamrén U
    J Clin Pharmacol; 2014 Dec; 54(12):1337-46. PubMed ID: 24895144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy: Spleen tyrosine kinase inhibitors--novel therapies for RA?
    Gómez-Puerta JA; Bosch X
    Nat Rev Rheumatol; 2011 Mar; 7(3):134-6. PubMed ID: 21304505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healing the Syk through kinase inhibitors.
    Rivera J; Colbert RA
    N Engl J Med; 2010 Sep; 363(14):1362-4. PubMed ID: 20879886
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.